IMAGING MASS SPECTROMETRY m/z 10165 m/z 4554 m/z 4940 Veronica Mainini PhD Biomedical Technologies Post-DOC researcher Clinical Proteomics Unit Dept. Of Health Science Università degli studi di Milano-Bicocca Mainini V. , Angel PM, Magni F., Caprioli RM. Rapid Communications in Mass Spectrometry 2011 25(1):199-204
81
Embed
IMAGING MASS SPECTROMETRY - web.medicina.unimib.itweb.medicina.unimib.it/magni/Corsi di Laurea in Biotecnologie Mediche... · (formalin-fixed paraffin-embedded) rimozione della paraffina
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
IMAGING MASS SPECTROMETRY
m/z 10165
m/z 4554
m/z 4940
Veronica Mainini PhD Biomedical Technologies Post-DOC researcher Clinical Proteomics Unit Dept. Of Health Science Università degli studi di Milano-Bicocca
Mainini V., Angel PM, Magni F., Caprioli RM. Rapid Communications in Mass Spectrometry 2011 25(1):199-204
IMAGING MASS SPECTROMETRY (IMS)
• Tecnologia che permette di analizzare componenti sia endogeni che esogeni presenti nei tessuti, mantenendo nel contempo la loro orientazione spaziale .
IMS
• Rileva analiti di varia natura
• Analisi condotta direttamente sul campione nativo
• Non necessita di marcatori, purificazioni, etc…
• Fornisce informazioni relative alla distribuzione spaziale
• Combina le informazioni molecolari ottenute mediante MS con informazioni derivanti dalla microscopia ottica.
Applicazioni TUMORE: definizione margini istologici e margini molecolari
Molecular Tumor Margin!
TUMORE ALLO STOMACO
• Non esistono Biomarker diagnostici affidabili
• CEA e CA19-9 non sono sufficientemente sensibili né specifici
• Difficile interpretazione istologica delle lesioni precancerose da quelle di stadio più avanzato.
Histology driven approach !!!
Controls n=43 Patients n=63
CTRL vs DISEASE
PCA
Sensitivity 94% Specificity 96%
SUMMARY
• Histology driven approach allowed to apply profiling analysis in order to:
- detect diagnostic pattern characterizing gastric cancer
- define molecular patterns discriminating intestinal and diffuse histological lesions
- differentiate stage Ia lesions to more advanced lesions (support to prognosis/aid in resolving ambiguous ultrasonography/TAC
Tissue Imaging by MS
MALDI IMS: Applications
Terapia adiuvante preoperatoria condotta con Paclitaxel + radioterapia: - Pazienti con risposta completa (pCR) - Pazienti che non rispondono alla terapia (NR)
α-defensine: peptidi ad effetto citotossico coinvolti nel processo di difesa mediato dai neutrofili
POTENZIALI MARKER PROGNOSTICI – RISPOSTA AL TRATTAMENTO
OLANZAPINA: 2-metil-4-(4-metilpiperazin-1-il)-10H-tieno[2,3-b][1,5] benzodiazepina, utilizzata per il trattamento di schizofrenia e disturbi bipolari.
BIBLIOGRAFIA – APPLICATIONS 1 - • Molecular analysis of tumor margins by MALDI mass spectrometry in renal
carcinoma. Oppenheimer SR, Mi D, Sanders ME, Caprioli RM. J Proteome Res. 2010 May 7;9(5):2182-90.
• Gastric cancer-specific protein profile identified using endoscopic biopsy samples via MALDI mass spectrometry. Kim HK, Reyzer ML, Choi IJ, Kim CG, Kim HS, Oshima A, Chertov O, Colantonio S, Fisher RJ, Allen JL, Caprioli RM, Green JE. J Proteome Res. 2010 Aug 6;9(8):4123-30. Erratum in: J Proteome Res. 2011 Jan 7;10(1):361.
• Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation Bauer JA, Chakravarthy BA, Rosenbluth JM et al. Clin Canc Res 2010; 16:681-690
• Direct molecular analysis of whole-body animal tissue sections by imaging MALDI mass spectrometry. Khatib-Shahidi S, Andersson M, Herman JL, Gillespie TA, Caprioli RM. Anal Chem. 2006 Sep 15;78(18):6448-56.
• Spatial and temporal alterations of phospholipids determined by mass spectrometry during mouse embryo implantation. Burnum KE, Cornett DS, Puolitaival SM, Milne SB, Myers DS, Tranguch S, Brown HA, Dey SK, Caprioli RM. J Lipid Res. 2009 Nov;50(11):2290-8.
• 3D Imaging by Mass Spectrometry: a new frontier Seeley EH, Caprioli RM Anal Chem 2012 Mar 6;84(5):2105-10.
•Imaging mass spectrometry of proteins and peptides: 3D volume proteomics Andersson M. Groseclose MR, Deutch AY, Caprioli RM Nat Meth vol 5, n.1 Jan2008; 101-108 • MALDI Imaging and Profiling Mass Spectrometry in Neuroproteomics. Andersson M, Andren P, Caprioli RM. In: Alzate O, editor. europroteomics. Boca Raton (FL): CRC Press; 2010. Chapter 7. • Proteomic analysis of formalin-fixed paraffin-embedded tissue by MALDI imaging mass spectrometry. Casadonte R, Caprioli RM. Nat Protoc. 2011 Oct 13;6(11):1695-709. •Enhancement of protein sensitivity for MALDI imaging mass spectrometry after chemical treatment of tissue sections Seeley EH, Oppenheimer SR, Deming M, Chaurand P, Caprioli RM J Am Soc Mass Spec 2008; 19(8): 1069-1077. • Detergent enhancement of on-tissue protein analysis by matrix-assisted laser desorption/ionization imaging mass spectrometry Mainini V, Angel PM, Magni F, Caprioli RM Rapid Comm Mass Spec 2011; 25: 199-204. • Detection of high molecular weight proteins by MALDI imaging mass spectrometry Mainini V, Bovo G, Chinello C, Gianazza E, Grasso M, Cattoretti G, Magni F. • Multiplex target protein imaging in tissue sections by mass spectrometry – TAMSIM Thiery G, Schepinov MS, Southern EM, et al RCM 2007; 21:823-829. • Tag-Mass: specific molecular imaging of transcriptome and proteome by mass spectrometry based on photocleavable tag. Lemaire R et al. J Prot Res 2007; 6(6):2057-2067. • Improvements of Targeted multiplex mass spectrometry Imaging. Thiery G, Anselmi E etal Proteomics 2008; 8:3725-3734